CAMCEVI KIT Drug Patent Profile

Name: CAMCEVI KIT Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Camcevi Kit, and what generic alternatives are available?

Camcevi Kit is a drug marketed by Accord and is included in one NDA. There are five patents protecting this drug.

This drug has forty patent family members in nineteen countries.

The generic ingredient in CAMCEVI KIT is leuprolide mesylate. There are twenty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the leuprolide mesylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Camcevi Kit

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 1, 2039. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for CAMCEVI KIT?
What are the global sales for CAMCEVI KIT?
What is Average Wholesale Price for CAMCEVI KIT?

Summary for CAMCEVI KIT

International Patents:	40
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	37
DailyMed Link:	CAMCEVI KIT at DailyMed

Drug patent expirations by year for CAMCEVI KIT

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for CAMCEVI KIT

Generic Entry Date for CAMCEVI KIT^: ⤷ Start Trial* Constraining patent/regulatory exclusivity: 11,717,555 NDA: 211488 Dosage: EMULSION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for CAMCEVI KIT

Drug Class	Gonadotropin Releasing Hormone Receptor Agonist
Mechanism of Action	Gonadotropin Releasing Hormone Receptor Agonists

US Patents and Regulatory Information for CAMCEVI KIT

CAMCEVI KIT is protected by five US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of CAMCEVI KIT is ⤷ Start Trial.

This potential generic entry date is based on patent 11,717,555.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Accord	CAMCEVI KIT	leuprolide mesylate	EMULSION;SUBCUTANEOUS	211488-001	May 25, 2021		RX	Yes	Yes	10,646,572	⤷ Start Trial	Y			⤷ Start Trial
Accord	CAMCEVI KIT	leuprolide mesylate	EMULSION;SUBCUTANEOUS	211488-001	May 25, 2021		RX	Yes	Yes	12,133,878	⤷ Start Trial	Y			⤷ Start Trial
Accord	CAMCEVI KIT	leuprolide mesylate	EMULSION;SUBCUTANEOUS	211488-001	May 25, 2021		RX	Yes	Yes	11,717,555	⤷ Start Trial	Y			⤷ Start Trial
Accord	CAMCEVI KIT	leuprolide mesylate	EMULSION;SUBCUTANEOUS	211488-001	May 25, 2021		RX	Yes	Yes	9,744,207	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for CAMCEVI KIT

When does loss-of-exclusivity occur for CAMCEVI KIT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 17443632
Estimated Expiration: ⤷ Start Trial

Brazil

Patent: 2020011774
Estimated Expiration: ⤷ Start Trial

Canada

Patent: 84339
Estimated Expiration: ⤷ Start Trial

China

Patent: 1511385
Estimated Expiration: ⤷ Start Trial

Patent: 8320058
Patent: 具有选定的释放持续时间的药物组合物 (Pharmaceutical composition with selected release duration)
Estimated Expiration: ⤷ Start Trial

European Patent Office

Patent: 27421
Patent: COMPOSITIONS PHARMACEUTIQUES AYANT UNE DURÉE DE LIBÉRATION CHOISIE (PHARMACEUTICAL COMPOSITIONS HAVING A SELECTED RELEASE DURATION)
Estimated Expiration: ⤷ Start Trial

Israel

Patent: 5448
Patent: תכשירים רוקחיים עם משך שחרור נבחר (Pharmaceutical compositions having a selected release duration)
Estimated Expiration: ⤷ Start Trial

Japan

Patent: 23021
Estimated Expiration: ⤷ Start Trial

Patent: 21516253
Patent: 選択された放出持続時間を有する医薬組成物
Estimated Expiration: ⤷ Start Trial

Mexico

Patent: 8984
Patent: COMPOSICIONES FARMACEUTICAS QUE TIENEN UNA DURACION DE LIBERACION SELECCIONADA (PHARMACEUTICAL COMPOSITIONS HAVING A SELECTED RELEASE DURATION)
Estimated Expiration: ⤷ Start Trial

Patent: 20006188
Patent: COMPOSICIONES FARMACEUTICAS QUE TIENEN UNA DURACION DE LIBERACION SELECCIONADA. (PHARMACEUTICAL COMPOSITIONS HAVING A SELECTED RELEASE DURATION.)
Estimated Expiration: ⤷ Start Trial

New Zealand

Patent: 6167
Patent: Pharmaceutical compositions having a selected release duration
Estimated Expiration: ⤷ Start Trial

Russian Federation

Patent: 56514
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ИМЕЮЩИЕ ВЫБРАННУЮ ПРОДОЛЖИТЕЛЬНОСТЬ ВЫСВОБОЖДЕНИЯ (PHARMACEUTICAL COMPOSITIONS WITH A SELECTED DURATION OF RELEASE)
Estimated Expiration: ⤷ Start Trial

Saudi Arabia

Patent: 0412229
Patent: تركيبات صيدلية لها فترة إطلاق مُختارة (PHARMACEUTICAL COMPOSITIONS HAVING A SELECTED RELEASE DURATION)
Estimated Expiration: ⤷ Start Trial

Singapore

Patent: 202004525T
Patent: PHARMACEUTICAL COMPOSITIONS HAVING A SELECTED RELEASE DURATION
Estimated Expiration: ⤷ Start Trial

South Korea

Patent: 2522654
Estimated Expiration: ⤷ Start Trial

Patent: 2567885
Estimated Expiration: ⤷ Start Trial

Patent: 210005542
Patent: 선택된 방출 기간을 갖는 약제학적 조성물
Estimated Expiration: ⤷ Start Trial

Patent: 230054755
Patent: 선택된 방출 기간을 갖는 약제학적 조성물 (Pharmaceutical Compositions Having a Selected Release Duration)
Estimated Expiration: ⤷ Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering CAMCEVI KIT around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Australia	2007207618		⤷ Start Trial
Brazil	PI0706558		⤷ Start Trial
Canada	2637569		⤷ Start Trial
China	101400363		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration